爱博医疗（688050）披露签订《投资意向书》公告，1月21日股价上涨0.78%

Core Viewpoint - Aibo Medical (688050) has announced plans to acquire at least 51% of Demai Medical, a leading company in the sports medicine sector in China, through a combination of acquisition loans and self-funding [1] Group 1: Company Performance - As of January 21, 2026, Aibo Medical's stock closed at 62.4 yuan, up 0.78% from the previous trading day, with a total market capitalization of 12.068 billion yuan [1] - The stock opened at 63.3 yuan, reached a high of 63.82 yuan, and a low of 62.01 yuan, with a trading volume of 3 billion yuan and a turnover rate of 2.46% [1] Group 2: Acquisition Details - Aibo Medical signed a Letter of Intent with Demai United Medical Technology Co., Ltd. and its founder Li Jianbo on January 20, 2026, to acquire a controlling stake in Demai Medical [1] - Demai Medical is recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small giant enterprise, holding 276 patents and covering the entire chain from preoperative prevention to surgical treatment and postoperative rehabilitation [1] - The transaction is subject to due diligence, formal agreement signing, and internal approval processes, and currently holds no legal binding force apart from confidentiality and exclusivity clauses [1]